AQR Capital Management LLC Has $72,000 Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

AQR Capital Management LLC trimmed its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 43.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,365 shares of the company’s stock after selling 8,039 shares during the period. AQR Capital Management LLC’s holdings in MiMedx Group were worth $72,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. ProShare Advisors LLC boosted its position in MiMedx Group by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock valued at $160,000 after buying an additional 1,631 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in MiMedx Group by 7.3% during the second quarter. Hsbc Holdings PLC now owns 34,343 shares of the company’s stock worth $233,000 after acquiring an additional 2,329 shares in the last quarter. Marshall Wace LLP raised its stake in shares of MiMedx Group by 1.1% in the 2nd quarter. Marshall Wace LLP now owns 298,818 shares of the company’s stock valued at $2,071,000 after purchasing an additional 3,223 shares during the period. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group in the 1st quarter valued at about $27,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of MiMedx Group by 13.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock valued at $254,000 after purchasing an additional 3,806 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDXG has been the topic of several recent research reports. StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, Craig Hallum lowered their target price on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Trading Down 0.2 %

Shares of MDXG stock opened at $5.82 on Friday. The company has a current ratio of 3.85, a quick ratio of 3.22 and a debt-to-equity ratio of 0.11. The stock has a market cap of $859.06 million, a P/E ratio of 13.23 and a beta of 1.97. The stock has a 50 day simple moving average of $6.15 and a 200 day simple moving average of $6.72. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $9.27.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The business had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. On average, research analysts predict that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.